Goldline Pharmaceutical IPO, which opened for subscription on Tuesday, May 12, will close today (May 14). The shares are set to debut on the BSE SME platform, with the tentative listing date scheduled for May 19. The share allotment is expected to be finalised on May 15.
Here's a look at the Goldline Pharmaceutical IPO details including the live subscription status, the latest GMP, and other important details investors should know as bidding enters its final day.
Goldline Pharmaceutical IPO Day 3 Subscription Status Live
According to BSE, the Goldline Pharmaceutical IPO was subscribed 233.29 times as of 11:10 am on Thursday. The issue received bids for 45,91,20,000 shares against the 19,68,000 shares on offer.
Retail investors drove the demand, subscribing to their portion 305.21 times. The Non-Institutional Investor (NII) category was booked 330.60 times, while the Qualified Institutional Buyers (QIB) segment saw a subscription of 18.29 times.
Goldline Pharmaceutical IPO Latest GMP
According to InvestorGain, Goldline Pharmaceutical SME IPO's latest GMP stands at Rs 25 on May 14. Based on the upper end of the price band of Rs 43, the estimated listing price stands at Rs 68 per share, implying a potential gain of 58.14% on listing.
Goldline Pharmaceutical IPO Details
Goldline Pharmaceutical IPO is a book-built issue of Rs 11.61 crore. The IPO consists entirely of a fresh issue of 27 lakh shares. The price band was fixed between Rs 41 and Rs 43 per share. The minimum lot size for retail investors is 3,000 shares. Retail investors must apply for at least two lots, or 6,000 shares, taking the minimum investment amount to Rs 2.58 lakh. For HNI investors, the minimum application size is three lots, or 9,000 shares, amounting to Rs 3.87 lakh.
Cumulative Capital Pvt. Ltd. is the book-running lead manager for the issue, while Bigshare Services Pvt. Ltd. is the registrar. Nirman Share Brokers Pvt. Ltd. is the market maker for the IPO.
About Goldline Pharmaceutical
Goldline Pharmaceutical operates across multiple therapeutic segments. The company's portfolio is divided into five segments. Goldline Pharma has 42 products focused on specialities such as orthopaedics, ENT, gastroenterology, neurology, urology and surgery.
Goldline Cardinal offers 54 products for physicians, diabetologists, endocrinologists and cardiologists. Goldline Aayushman includes 18 products catering to paediatricians, neonatologists and child specialists. Goldline InLife has 22 products aimed at intensivists, critical care consultants and super-speciality surgeons. Goldline Wellness includes 10 products focused on supportive care in cancer treatment.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.